Ophthalmic Medications in Pediatric Patients

Teresa M. Myers, MD; David K. Wallace, MD; Sandra M. Johnson, MD

Compr Ophthalmol Update. 2005;6(2):85-101.

Conclusion

While recent legal and economic incentives have encouraged pharmaceutical companies to obtain more data regarding dosing, efficacy, and side effects of medications used in pediatric preparations, there are still problems obtaining adequate patient sample sizes and objective measurement of symptoms and outcomes for such studies. Pediatric dosage information has become slowly available, but many of the medications commonly used in children still do not have pediatric dosing labeling, presenting a dilemma when treating these patients. Infants and neonates in particular are subject to a much greater risk of systemic side effects. Physicians should consider carefully the risk/benefit profile when prescribing eye drops in children to establish the appropriate dosage while minimizing risk, and monitor patients closely during and after treatment for local and systemic side effects.

1 2 3 4 5 6 7 8

Next Section

Reprint Address

David K. Wallace, MD, UNC Dept of Ophthalmology, 5105 Bioinformatics; CB #7040, Chapel Hill, NC 27599-7040. email: david_wallace@med.unc.edu

Cite this: Ophthalmic Medications in Pediatric Patients - Medscape - Mar 01, 2005.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Ophthalmic Medications in Pediatric Patients

Conclusion

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Sidebar

Sidebar: Focus Points

Comments

Email This

Feedback